Abstract
The contributors to this volume have raised many interesting ideas and proposals about the future direction of atherosclerosis research in the short and long term. The important information that has been gathered from clinical trials and the accomplishments of the late 1980s outline a highly impressive story. We now have firm evidence that the incidence of coronary heart disease (CHD) in the form of myocardial infarction and/or coronary death can be reduced - in both symptomatic and asymptomatic populations — by lipid modification; specifically, reduction in serum levels of low-density lipoprotein (LDL) cholesterol combined with increased serum levels of high-density lipoprotein (HDL) cholesterol. To choose where to go next in this research requires that we look at where we have been.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Blankenhom DH, Nessim SA, Johnson RL et al. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233–3240
Blankenhom DH, Alaupovic P, Wickham W, Chin HP, Azen SP (1990a) Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 81:694–696
Blankenhom DH, Johnson RL, Mack WJ, El Zein HA, Vailas LI (1990b) The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 263:1646–1652
Brown G, Albers JJ, Fisher LD et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289–1298
Buchwald H, Varco R, Matts J et al. (1990) Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 323:946–955
Cashin-Hemphill L, Mack WJ, Pogoda JM et al. (1990) Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 264:3013–3017
Gordon D, Probstfield J, Garrison R et al. (1989) High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies: Circulation 79:8–15
Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007–3012
Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:641–651
Manninen V, Elo MO, Frick MH et al. (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641–651
Ornish D, Brown SE, Scherwitz SW et al. (1990) Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 336:129–133
Rossouw JE, Lewis B, Rifkind BM (1990) The value of lowering cholesterol after myocardial infarction. N Engl J Med 323:1112–1119
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag London Limited
About this chapter
Cite this chapter
Gotto, A.M. (1992). Cholesterol-Lowering Clinical Trials: Where Do We Go From Here?. In: Gotto, A.M. (eds) Cellular and Molecular Biology of Atherosclerosis. Argenteuil Symposia. Springer, London. https://doi.org/10.1007/978-1-4471-1909-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1909-8_16
Publisher Name: Springer, London
Print ISBN: 978-1-4471-1911-1
Online ISBN: 978-1-4471-1909-8
eBook Packages: Springer Book Archive